iX Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
iX Biopharma has a total shareholder equity of SGD4.3M and total debt of SGD4.7M, which brings its debt-to-equity ratio to 107.6%. Its total assets and total liabilities are SGD14.6M and SGD10.3M respectively.
Key information
107.6%
Debt to equity ratio
S$4.67m
Debt
| Interest coverage ratio | n/a |
| Cash | S$1.84m |
| Equity | S$4.34m |
| Total liabilities | S$10.28m |
| Total assets | S$14.62m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 42C's short term assets (SGD6.6M) do not cover its short term liabilities (SGD7.4M).
Long Term Liabilities: 42C's short term assets (SGD6.6M) exceed its long term liabilities (SGD2.9M).
Debt to Equity History and Analysis
Debt Level: 42C's net debt to equity ratio (65.1%) is considered high.
Reducing Debt: 42C's debt to equity ratio has increased from 18.7% to 107.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 42C has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 42C is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.